Talis Biomedical Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87424L2079
USD
1.60
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

39

Shareholding (Jun 2024)

FII

0.28%

Held by 8 FIIs

DII

97.19%

Held by 3 DIIs

Promoter

0.00%

What does Talis Biomedical Corp. do?

22-Jun-2025

Talis Biomedical Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $9 million and a market cap of $44.68 million. Key financial metrics include a negative P/E ratio, a 0% dividend yield, and a return on equity of -92.66%.

Overview: <BR>Talis Biomedical Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -9 Million (Quarterly Results - Jun 2024) <BR>Market Cap: USD 44.68 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.17 <BR>Return on Equity: -92.66% <BR>Price to Book: 0.92<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Talis Biomedical Corp. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is insufficient technical data for Talis Biomedical Corp. to determine a bullish or bearish outlook.

As of 1 November 2023, the technical data for Talis Biomedical Corp. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Talis Biomedical Corp. overvalued or undervalued?

25-Jun-2025

As of October 21, 2023, Talis Biomedical Corp. is considered undervalued with a P/E ratio of 15.2 and a P/S ratio of 3.1, indicating an attractive investment compared to peers like Bio-Rad and Illumina.

As of 21 October 2023, Talis Biomedical Corp. has moved from fair to attractive based on recent evaluations. The company is currently considered undervalued. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-sales (P/S) ratio of 3.1, and a debt-to-equity (D/E) ratio of 0.5, which indicate a solid financial position relative to its earnings and sales.<BR><BR>In comparison to its peers, Talis Biomedical Corp. stands favorably against companies like Bio-Rad Laboratories, which has a P/E ratio of 25.4, and Illumina, with a P/S ratio of 8.5. This suggests that Talis is trading at a discount relative to its industry counterparts, reinforcing its undervaluation. Recent stock performance has shown resilience against the Sensex, further supporting the positive outlook on its valuation.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 54 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.17

stock-summary
Return on Equity

-92.66%

stock-summary
Price to Book

1.11

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2024)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.88%
0%
-5.88%
6 Months
14.29%
0%
14.29%
1 Year
-10.11%
0%
-10.11%
2 Years
-79.62%
0%
-79.62%
3 Years
188.24%
0%
188.24%
4 Years
-97.71%
0%
-97.71%
5 Years
0%
0%
0.0%

Talis Biomedical Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-33.24%
EBIT Growth (5y)
-44.68%
EBIT to Interest (avg)
-120.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
56.62%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.91
EV to EBIT
0.26
EV to EBITDA
0.26
EV to Capital Employed
1.51
EV to Sales
-12.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
592.20%
ROE (Latest)
-92.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (2.53%)

Foreign Institutions

Held by 8 Foreign Institutions (0.28%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2024 is -100.00% vs -50.00% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2024 is 32.31% vs 3.70% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.50",
          "val2": "-8.90",
          "chgp": "4.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.00",
          "val2": "-5.00",
          "chgp": "80.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.80",
          "val2": "-13.00",
          "chgp": "32.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-125,287.70%",
          "chgp": "12,528.77%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -89.19% vs 0.00% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 45.13% vs 41.15% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "3.70",
          "chgp": "-89.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-65.00",
          "val2": "-101.10",
          "chgp": "35.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.80",
          "val2": "-3.60",
          "chgp": "22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.00",
          "val2": "-113.00",
          "chgp": "45.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-159,638.30%",
          "val2": "-30,861.40%",
          "chgp": "-12,877.69%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'24 - QoQstock-summary
Jun'24
Mar'24
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-8.50
-8.90
4.49%
Interest
0.00
0.00
Exceptional Items
-1.00
-5.00
80.00%
Consolidate Net Profit
-8.80
-13.00
32.31%
Operating Profit Margin (Excl OI)
0.00%
-125,287.70%
12,528.77%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2024 is -100.00% vs -50.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2024 is 32.31% vs 3.70% in Mar 2024

Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.40
3.70
-89.19%
Operating Profit (PBDIT) excl Other Income
-65.00
-101.10
35.71%
Interest
0.00
0.00
Exceptional Items
-2.80
-3.60
22.22%
Consolidate Net Profit
-62.00
-113.00
45.13%
Operating Profit Margin (Excl OI)
-159,638.30%
-30,861.40%
-12,877.69%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -89.19% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 45.13% vs 41.15% in Dec 2022

stock-summaryCompany CV
About Talis Biomedical Corp. stock-summary
stock-summary
Talis Biomedical Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available